[go: up one dir, main page]

RU2000111506A - PROLONGED TABLETS FOR THE TREATMENT OF PARKINSON'S DISEASE - Google Patents

PROLONGED TABLETS FOR THE TREATMENT OF PARKINSON'S DISEASE

Info

Publication number
RU2000111506A
RU2000111506A RU2000111506/14A RU2000111506A RU2000111506A RU 2000111506 A RU2000111506 A RU 2000111506A RU 2000111506/14 A RU2000111506/14 A RU 2000111506/14A RU 2000111506 A RU2000111506 A RU 2000111506A RU 2000111506 A RU2000111506 A RU 2000111506A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
composition according
cps
usp
parkinson
Prior art date
Application number
RU2000111506/14A
Other languages
Russian (ru)
Other versions
RU2205007C2 (en
Inventor
Тцу-чи Роберт ДЗУ
Original Assignee
Фармация Энд Апджон Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармация Энд Апджон Компани filed Critical Фармация Энд Апджон Компани
Publication of RU2000111506A publication Critical patent/RU2000111506A/en
Application granted granted Critical
Publication of RU2205007C2 publication Critical patent/RU2205007C2/en

Links

Claims (1)

1. Фармацевтическая композиция, представляющая собой таблетку с пролонгированным выделением для перорального введения, которая содержит
(a)(R)-5,6-дигидро-5-(метиламино)-4Н-имидазо [4,5-ij)] -хинолин-2(1Н)-он (Z)-2-бутендиоат (1: 1) 0,3%-16%
(b) крахмал 60%-69%
(c) гидроксипропилметилцеллюлозу 30%-40%
2. Фармацевтическая композиция по п. 1, которая включает
(a) (R)-5,6-дигидро-5-(метиламино)-4Н-имидазо [4,5-ij)] -хинолин-2(1Н)-он(Z)-2-бутендиоат (1: 1) 0,44%-10%
(b) преклейстеризованный или кукурузный крахмал 60%-67%
(c) гидроксипропилметилцеллюлозу 30%-40%
3. Фармацевтическая композиция по п. 1, в которой (R)-5,6-дигидро-5-(метиламино)-4Н-имидазо[4,5-ij] ] -хинолин-2(1Н)-он (Z)-2-бутендиоат (1: 1) присутствует в количестве от около 0,3% (1 мг) до около 16% (56 мг)/таблетку.1. The pharmaceutical composition, which is a tablet with a prolonged release for oral administration, which contains
(a) (R) -5,6-dihydro-5- (methylamino) -4H-imidazo [4,5-ij)] -quinoline-2 (1H) -one (Z) -2-butenedioate (1: 1 ) 0.3% -16%
(b) starch 60% -69%
(c) hydroxypropyl methyl cellulose 30% -40%
2. The pharmaceutical composition according to claim 1, which includes
(a) (R) -5,6-dihydro-5- (methylamino) -4H-imidazo [4,5-ij)] -quinoline-2 (1H) -one (Z) -2-butenedioate (1: 1 ) 0.44% -10%
(b) pre-pasteurized or corn starch 60% -67%
(c) hydroxypropyl methyl cellulose 30% -40%
3. The pharmaceutical composition according to claim 1, in which (R) -5,6-dihydro-5- (methylamino) -4H-imidazo [4,5-ij]] -quinoline-2 (1H) -one (Z) -2-butenedioate (1: 1) is present in an amount of about 0.3% (1 mg) to about 16% (56 mg) / tablet. 4. Фармацевтическая композиция по п. 1, в которой (R)-5,6-дигидро-5-(метиламино)-4Н-имидазо[4,5-ij] ] -хинолин-2(1Н)-он (Z)-2-бутендиоат (1: 1) присутствует в количестве около 0,44% (1,5 мг), 0,88% (3,1 мг), 1,76% (6,2 мг), 3,52% (12,3 мг) и 5,33% (19 мг)/таблетку. 4. The pharmaceutical composition according to claim 1, in which (R) -5,6-dihydro-5- (methylamino) -4H-imidazo [4,5-ij]] -quinoline-2 (1H) -one (Z) -2-butenedioate (1: 1) is present in an amount of about 0.44% (1.5 mg), 0.88% (3.1 mg), 1.76% (6.2 mg), 3.52% (12.3 mg) and 5.33% (19 mg) / tablet. 5. Фармацевтическая композиция по п. 1, в которой крахмал является преклейстеризованным или кукурузным крахмалом. 5. The pharmaceutical composition according to claim 1, in which the starch is pre-pasteurized or corn starch. 6. Фармацевтическая композиция по п. 1, в которой крахмал представляет собой смесь преклейстеризованного и кукурузного крахмала. 6. The pharmaceutical composition according to claim 1, in which the starch is a mixture of pre-pasteurized and corn starch. 7. Фармацевтическая композиция по п. 1, в которой гидроксипропилметилцеллюлозу выбирают из группы, включающей:
гидроксипропилметилцеллюлозу 2208 USP 100 сПз,
гидроксипропилметилцеллюлозу 2208 USP 4000 сПз,
гидроксипропилметилцеллюлозу 2208 USP 15000 сПз,
гидроксипропилметилцеллюлозу 2208 USP 100000 сПз,
гидроксипропилметилцеллюлозу 2910 USP 4000 сПз,
гидроксипропилметилцеллюлозу 2910 USP 10000 сПз
или их смеси.7. The pharmaceutical composition according to claim 1, in which hydroxypropylmethyl cellulose is selected from the group including:
hydroxypropyl methylcellulose 2208 USP 100 cps,
hydroxypropyl methylcellulose 2208 USP 4000 cps,
hydroxypropyl methylcellulose 2208 USP 15,000 cps,
hydroxypropyl methylcellulose 2208 USP 100,000 cps,
hydroxypropyl methylcellulose 2910 USP 4000 cps,
hydroxypropyl methylcellulose 2910 USP 10,000 cps
or mixtures thereof. 8. Фармацевтическая композиция по п. 7, в которой гидроксипропилметилцеллюлоза представляет собой гидроксипропилметилцеллюлозу 2208 USP 4000 спз или гидроксипропилметилцеллюлозу 2910 USP 4000 сПз. 8. The pharmaceutical composition of claim 7, wherein the hydroxypropyl methyl cellulose is hydroxypropyl methyl cellulose 2208 USP 4000 cps or hydroxypropyl methyl cellulose 2910 USP 4000 cps. 9. Фармацевтическая композиция по п. 1, которая дополнительно содержит стеарат магния. 9. The pharmaceutical composition according to claim 1, which further comprises magnesium stearate. 10. Фармацевтическая композиция по п. 9, в которой стеарат магния присутствует в количестве от около 0,2 до около 2,0%. 10. The pharmaceutical composition according to claim 9, in which magnesium stearate is present in an amount of from about 0.2 to about 2.0%. 11. Фармацевтическая композиция по п. 1, которая дополнительно содержит коллоидную двуокись кремния. 11. The pharmaceutical composition according to claim 1, which further comprises colloidal silicon dioxide. 12. Фармацевтическая композиция по п. 11, в которой коллоидная двуокись кремния присутствует в количестве от около 0,2 до около 1,0%. 12. The pharmaceutical composition according to claim 11, in which colloidal silicon dioxide is present in an amount of from about 0.2 to about 1.0%. 13. Фармацевтическая композиция по п. 1, где общий вес таблетки составляет около 350 мг. 13. The pharmaceutical composition according to claim 1, wherein the total weight of the tablet is about 350 mg. 14. Способ лечения человека, страдающего болезнью Паркинсона, который включает пероральное введение эффективного против болезни Паркинсона количества (R)-5,6-дигидро-5-(метиламино)-4Н-имидазо[4,5-ij] ] -хинолин-2(1Н)-она (Z)-2-бутендиоат (1: 1). 14. A method of treating a person suffering from Parkinson’s disease, which comprises oral administration of an effective amount of (R) -5,6-dihydro-5- (methylamino) -4H-imidazo [4,5-ij]] -quinoline-2 against Parkinson's disease (1H) -one (Z) -2-butenedioate (1: 1). 15. Способ лечения человека, страдающего болезнью Паркинсона по п. 14, в котором (R)-5,6-дигидро-5-(метиламино)-4Н-имидазо[4,5-ij] ] -хинолин-2(1Н)-он (Z)-2-бутендиоат (1: 1) вводят дважды в день. 15. A method of treating a person suffering from Parkinson's disease according to claim 14, in which (R) -5,6-dihydro-5- (methylamino) -4H-imidazo [4,5-ij]] -quinoline-2 (1H) -one (Z) -2-butenedioate (1: 1) is administered twice daily. 16. Способ лечения человека, страдающего болезнью Паркинсона по п. 14, в котором эффективное количество составляет от около 2 мг до около 112 мг/день. 16. A method of treating a person suffering from Parkinson's disease according to claim 14, wherein the effective amount is from about 2 mg to about 112 mg / day. 17. Способ лечения человека, страдающего болезнью Паркинсона по п. 16, в котором эффективное количество составляет от около 3 мг до около 70 мг/день. 17. A method of treating a person suffering from Parkinson's disease according to claim 16, wherein the effective amount is from about 3 mg to about 70 mg / day.
RU2000111506/14A 1997-09-30 1998-09-03 Sustained-release tablets for parkinson's disease treatment RU2205007C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6082797P 1997-09-30 1997-09-30
US60/060,827 1997-09-30

Publications (2)

Publication Number Publication Date
RU2000111506A true RU2000111506A (en) 2002-05-10
RU2205007C2 RU2205007C2 (en) 2003-05-27

Family

ID=22031996

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2000111506/14A RU2205007C2 (en) 1997-09-30 1998-09-03 Sustained-release tablets for parkinson's disease treatment

Country Status (22)

Country Link
US (2) US6197339B1 (en)
EP (1) EP1017391B1 (en)
JP (1) JP2001517701A (en)
KR (1) KR100516095B1 (en)
CN (1) CN1195518C (en)
AT (1) ATE297208T1 (en)
AU (1) AU742941B2 (en)
BR (1) BR9812687A (en)
CA (1) CA2301869A1 (en)
DE (1) DE69830503T2 (en)
DK (1) DK1017391T3 (en)
ES (1) ES2242296T3 (en)
FI (1) FI20000720A7 (en)
HU (1) HUP0004586A2 (en)
NO (1) NO320303B1 (en)
NZ (1) NZ504221A (en)
PL (1) PL191125B1 (en)
PT (1) PT1017391E (en)
RU (1) RU2205007C2 (en)
SI (1) SI1017391T1 (en)
SK (1) SK3612000A3 (en)
WO (1) WO1999016442A2 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ513347A (en) 1999-02-05 2003-01-31 Upjohn Co 1,2,5,6-tetrahydro-4H-imidazo[4,5,1-ij]-quinolin-2(1H)-one derivatives
EP1169024B1 (en) 1999-03-31 2005-12-21 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
AR031152A1 (en) * 2000-10-31 2003-09-10 Upjohn Co NEW TREATMENTS FOR THE CONCERNED LEG SYNDROME
FR2825705B1 (en) * 2001-06-08 2005-05-20 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-BACTERIANS
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
AU2002360600B2 (en) * 2001-12-11 2007-11-29 University Of Virginia Patent Foundation Use of pramipexole to treat amyotrophic lateral sclerosis
FR2835186B1 (en) 2002-01-28 2006-10-20 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS ACTIVE AS BETA-LACTAMASES INHIBITORS
PL223471B1 (en) * 2002-03-15 2016-10-31 Cypress Bioscience Inc Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
AR040683A1 (en) * 2002-07-25 2005-04-13 Pharmacia Corp COMPOSITION OF SUSTAINED RELEASE TABLETS INCLUDED BY AN AGONIST OF DOPAMINE RECEIVERS
AR040680A1 (en) * 2002-07-25 2005-04-13 Pharmacia Corp COMPOSITION OF SUSTAINED RELEASE TABLETS
PE20040134A1 (en) * 2002-07-25 2004-03-06 Pharmacia Corp PRAMIPEXOL ONCE-A-DAY DOSAGE FORM
FR2844273B1 (en) 2002-09-05 2008-04-04 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS, METHOD AND INTERMEDIARY PREPARATION AND USE AS MEDICAMENT, IN PARTICULAR AS INHIBITORS OF BETA-LACTAMASES AND ANTI-BACTERIALS.
JP2006507266A (en) * 2002-10-04 2006-03-02 ファルマシア・コーポレーション Compositions and methods for treating sexual dysfunction
EP1546120A4 (en) * 2002-10-04 2006-11-22 Pharmacia Corp Pharmaceutical compositions for treatment of parkinson's disease
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
BR0315517A (en) * 2002-10-25 2005-08-09 Pharmacia & Upjohn Co Llc Use of heterocyclically amine type compounds as neuroprotective agents
AU2004207578B2 (en) * 2003-01-28 2007-06-28 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
US20050020589A1 (en) * 2003-06-18 2005-01-27 Pfizer Inc. Sustained-release tablet composition comprising a dopamine receptor agonist
UA95993C2 (en) * 2004-08-13 2011-09-26 Бёрингер Ингельхайм Интернациональ Гмбх Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
UA86831C2 (en) * 2004-08-13 2009-05-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Extended release tablet formulation comprising pramipexole or pharmaceutically acceptable salt thereof, method for its manufacturing and administration
DE602006009670D1 (en) * 2005-08-15 2009-11-19 Univ Virginia NEURORESTAURATION WITH R (+) PRAMIPEXOL
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
US20090041844A1 (en) * 2006-02-10 2009-02-12 Boehringer Ingelheim International Gmbh Modified Release Formulation
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
ES2379117T3 (en) 2006-05-16 2012-04-20 Knopp Neurosciences, Inc. Compositions of R (+) and S (-) pramipexole and methods of use thereof
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
WO2008113056A2 (en) 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
CN102186350A (en) * 2008-08-19 2011-09-14 诺普神经科学股份有限公司 Compositions and methods of using (r)-pramipexole
EP2758435A1 (en) 2011-09-23 2014-07-30 Roche Glycart AG Bispecific anti-egfr/anti igf-1r antibodies
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9463186B2 (en) 2013-04-15 2016-10-11 Northwestern University Treatment for dopaminergic disorders
SMT202100119T1 (en) 2013-07-12 2021-05-07 Knopp Biosciences Llc Treating elevated levels of eosinophils and/or basophils
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
EP3038467B1 (en) 2013-08-13 2020-07-29 Knopp Biosciences LLC Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
AU2014306597B2 (en) 2013-08-13 2018-05-17 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
AU2021464980A1 (en) * 2021-09-17 2024-05-02 Hinova Pharmaceuticals Inc. Quinoline compound sustained-release tablet and preparation method therefor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US5273975A (en) 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
DK0480939T3 (en) * 1989-06-09 1995-07-10 Upjohn Co Heterocyclic amines with effect on the central nervous system
US5000962A (en) 1989-08-25 1991-03-19 Schering Corporation Long acting diltiazem formulation
FR2667864B2 (en) * 1990-03-07 1994-08-05 Rhone Poulenc Sante N-PHENYL GLYCINAMIDE DERIVATIVES, THEIR PREPARATION AND THE MEDICINAL PRODUCTS CONTAINING THEM.
GB9605857D0 (en) 1996-03-20 1996-05-22 Tester Richard F Polysaccharides as chemical release systems
CA2173818A1 (en) 1996-04-10 1997-10-11 Francois Chouinard Time-released pharmaceutical compound containing a cured amylose-based support and hydroxypropylmethylcellulose

Similar Documents

Publication Publication Date Title
RU2000111506A (en) PROLONGED TABLETS FOR THE TREATMENT OF PARKINSON'S DISEASE
CA2257431C (en) Fast-dissolving galanthamine hydrobromide tablet
US4309405A (en) Sustained release pharmaceutical compositions
US4309406A (en) Sustained release pharmaceutical compositions
CA1147651A (en) Sustained release pharmaceutical compositions
TW576743B (en) Extended release formulations of erythromycin derivatives
AU705488B2 (en) Controlled release of drugs delivered by sublingual or buccal administration
CA2289260C (en) Controlled release of drugs delivered by sublingual or buccal administration
CA2601289A1 (en) Once-a-day oxycodone formulations
JP2002528408A (en) Controlled release pharmaceutical formulation containing cGMPPDE-5 inhibitor
JP2003531165A (en) Composition
JP2003519181A (en) Methods and formulations for treating resistance to antihypertensives and related conditions
JP5561885B2 (en) A new formulation of mirtazapine
JP2002543128A (en) Treatment of female arousal disorder
NZ207768A (en) Sustained release tablets comprising dipyridamole
CA2180703A1 (en) Fast-dissolving galanthamine hydrobromide tablet
NZ535261A (en) A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
JP2005320254A (en) Hypnotic composition
US20040192706A1 (en) Method and compositions for treating anxiety
WO1995033451A1 (en) Non-sedating allergy sinus medication
WO1996026722A1 (en) Use of isosorbide-5-mononitrate
MXPA97006492A (en) Use of isosorb 5-mononitrate
HU226132B1 (en) Fast-dissolving galanthamine hydrobromide tablet
AU7265898A (en) Controlled release of drugs delivered by sublingual or buccal administration